We are live on
!
Find out more
VA
VR Adviser Portfolio holdings
AUM
$2.68B
1-Year Est. Return
422.73%
This Fund
S&P 500
This Quarter
Est. Return
+60.07%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$1.46B
AUM Growth
+$508M
(+53%)
Cap. Flow
+$101M
Cap. Flow
% of AUM
6.94%
Top 10 Holdings %
Top 10 Hldgs %
68.34%
Holding
42
New
5
Increased
14
Reduced
8
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pharvaris
PHVS
|
+$37.1M |
| 2 |
Spyre Therapeutics
SYRE
|
+$28.6M |
| 3 |
Ocular Therapeutix
OCUL
|
+$23M |
| 4 |
ATXS
Astria Therapeutics
ATXS
|
+$17.8M |
| 5 |
Arvinas
ARVN
|
+$14.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Travere Therapeutics
TVTX
|
+$23.5M |
| 2 |
Rhythm Pharmaceuticals
RYTM
|
+$18.7M |
| 3 |
Savara
SVRA
|
+$14.1M |
| 4 |
GH Research
GHRS
|
+$10.1M |
| 5 |
Taysha Gene Therapies
TSHA
|
+$8.04M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LYRA
26
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $13.5M | 0.93% |
51,512
+33,029
| +179% | +$5.98M |
|
|
ABVX
27
Abivax
ABVX
$10.9B
| $10.7M | 0.73% |
+998,570
| New | +$10.2M |
|
28
Dianthus Therapeutics
DNTH
$5.84B
| $9.65M | 0.66% |
927,706
| – | – |
|
29
Praxis Precision Medicines
PRAX
$8.58B
| $7.88M | 0.54% |
353,626
-1
| -0% | -$18 |
|
|
30
GH Research
GHRS
$1.93B
| $7.65M | 0.52% |
1,318,327
-1,425,798
| -52% | -$10.1M |
|
|
SLRN
31
DELISTED
ACELYRIN
SLRN
| $6.99M | 0.48% |
937,113
+72,781
| +8% | +$621K |
|
32
EyePoint Inc
EYPT
$1.03B
| $5.78M | 0.4% |
+250,000
| New | +$2.79M |
|
33
Trevi Therapeutics
TRVI
$2.59B
| $4.59M | 0.31% |
3,422,397
| – | – |
|
|
ADVM
34
DELISTED
Adverum Biotechnologies
ADVM
| $3.88M | 0.27% |
514,755
-142,575
| -22% | -$1.3M |
|
35
Milestone Pharmaceuticals
MIST
$138M
| $1.54M | 0.11% |
925,048
-1,283,764
| -58% | -$3.48M |
|
36
Olema Pharmaceuticals
OLMA
$1B
| $1.08M | 0.07% |
77,042
| – | – |
|
37
Aclaris Therapeutics
ACRS
$726M
| – | – |
-1,040,754
| Closed | -$7.13M |
|
|
AFMD
38
DELISTED
Affimed
AFMD
| – | – |
-142,857
| Closed | -$683K |
|
39
Pliant Therapeutics
PLRX
$64.4M
| – | – |
-288,949
| Closed | -$5.01M |
|
40
Rallybio
RLYB
$84.5M
| – | – |
-33,567
| Closed | -$905K |
|
41
Sagimet Biosciences
SGMT
$439M
| – | – |
-515,000
| Closed | -$4.53M |
|
|
42
Travere Therapeutics
TVTX
$5.2B
| – | – |
-2,623,677
| Closed | -$23.5M |
|
Similar funds
MMEA
WGI
TCAM
SFI
HC
CI
PCA
LP
VR Adviser's Q4 2023 Portfolio in Review
As of Q4 2023, VR Adviser held 42 positions worth $1.46B, up 53% from $950M the previous quarter. Its ten largest holdings account for 68% of the portfolio.
VR Adviser deployed $101M of net new capital in Q4 2023, opening 5 new positions and adding to 14 existing holdings. Its largest new stake was Ocular Therapeutix: 7,775,760 shares worth $34.7M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Rhythm Pharmaceuticals, an estimated $18.7M trimmed.
- VR Adviser's largest Q4 2023 buy was Ocular Therapeutix: 7,775,760 shares worth $34.7M.
- VR Adviser added most to Pharvaris in Q4 2023, an estimated $37.1M increase.
- VR Adviser's biggest Q4 2023 reduction was Rhythm Pharmaceuticals, cutting an estimated $18.7M.
- VR Adviser fully exited Travere Therapeutics in Q4 2023, selling an estimated $23.5M.
- VR Adviser's ten largest holdings make up 68% of its $1.46B portfolio in Q4 2023.
- VR Adviser opened 5 new positions and closed 6 in Q4 2023.
- VR Adviser's portfolio value rose 53% quarter-over-quarter to $1.46B.
Based on VR Adviser's 13F filing for Q4 2023, filed 14 Feb 2024.